Knockdown of fat mass and obesity alleviates the ferroptosis in Parkinson's disease through m6A-NRF2-dependent manner

Cell Biol Int. 2024 Apr;48(4):431-439. doi: 10.1002/cbin.12118. Epub 2024 Jan 5.

Abstract

Emerging evidence has suggested that N6 -methyladenosine (m6 A) regulates the pathology of Parkinson's disease (PD). Nevertheless, the function of demethylase fat mass and obesity (FTO) associated pathogenesis is still not fully elucidated. Here, this research findings revealed that m6 A-modification was decreased in PD models, meanwhile, the FTO level upregulated in the PD models. Functionally, in N-methyl-4-phenylpyridinium (MPP+) treated SH-SY5Y cells, the ferroptosis significantly upregulated and FTO silencing mitigated the ferroptosis phenotype. Moreover, in silico assays indicated that nuclear factor erythroid 2-related factor-2 (NRF2) acted as the target of FTO, and FTO demethylated the m6 A modification from NRF2 mRNA. Furthermore, FTO impaired the NRF2 mRNA stability via m6 A-dependent pathway. Thus, our findings illustrated an important role of FTO on PD through m6 A-NRF2-ferroptosis manner. Taken together, the study revealed the potential function of FTO on PD nervous system diseases.

Keywords: N6-methyladenosine; Parkinson's disease; fat mass and obesity; ferroptosis; nuclear factor erythroid 2-related factor-2.

MeSH terms

  • 1-Methyl-4-phenylpyridinium
  • Adenine / analogs & derivatives*
  • Alpha-Ketoglutarate-Dependent Dioxygenase FTO / genetics
  • Ferroptosis*
  • Humans
  • NF-E2-Related Factor 2 / genetics
  • Neuroblastoma*
  • Obesity / genetics
  • Parkinson Disease* / genetics

Substances

  • 6-methyladenine
  • NF-E2-Related Factor 2
  • 1-Methyl-4-phenylpyridinium
  • FTO protein, human
  • Alpha-Ketoglutarate-Dependent Dioxygenase FTO
  • Adenine